UDLCO CRH CPC: Is pulmonary fungal infection detected on autopsy a cause of death or an indicator of imminent irreversible multi organ failure?

Introduction

The clinical management of refractory hematological malignancies is frequently confounded by overlapping manifestations of disease progression, treatment toxicity, and opportunistic infections. In this case, a 32-year-old male with transformed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and secondary Hemophagocytic Lymphohistiocytosis (HLH) experienced rapid multi-organ failure. The central Socratic inquiry asks: Is invasive pulmonary aspergillosis (IPA) detected on autopsy a primary cause of death, or merely an indicator of irreversible, impending multi-organ failure (MODS)?

CC licence: https://en.wikipedia.org/wiki/File:Pulmonary_angioinvasive_aspergillosis.jpg

Methods

A retrospective analysis of the clinical trajectory, serial laboratory investigations, advanced imaging, and complete post-mortem autopsy findings (PM No. 33078) was conducted to correlate antemortem clinical impressions with post-mortem pathological revelations.

Results

Antemortem evaluations attributed the patient's deterioration to refractory septic shock, disseminated intravascular coagulation (DIC), and secondary HLH, with blood and urine cultures remaining persistently sterile. However, the complete autopsy revealed definitive, previously unsuspected angioinvasive pulmonary aspergillosis characterized by hemorrhagic pulmonary nodules in both lower lobes. Furthermore, the autopsy confirmed systemic transformation to T-cell/Histiocyte-Rich Large B-cell Lymphoma (THRLBCL) involving the liver, spleen, and bone marrow, alongside secondary hemophagocytosis and acute tubular necrosis (ATN).

Discussion (The Steelman Perspective)

Argument: Invasive pulmonary aspergillosis in this immunocompromised host was not merely a passive epiphenomenon or a marker of dying organs; it functioned as an active, independent catalyst of lethal respiratory failure and systemic septic shock.

In profoundly immunosuppressed patients with neutropenia, high-dose corticosteroids, and etoposide exposure, angioinvasive fungi rapidly destroy pulmonary vasculature, causing local hemorrhage, gas exchange failure (Type-I respiratory failure), and a secondary systemic inflammatory cascade. While MODS and HLH create the vulnerable milieu, the angioinvasion itself represents a direct, catastrophic mechanical and infectious insult that converts a precarious physiological state into irreversible cardiac arrest. Autopsy data consistently demonstrates that opportunistic mycoses are frequently underdiagnosed antemortem, making them primary structural drivers of mortality rather than secondary biomarkers.

Keywords

Invasive Pulmonary Aspergillosis | Autopsy Findings | Hemophagocytic Lymphohistiocytosis (HLH) | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma (THRLBCL) | Multi-Organ Dysfunction Syndrome (MODS) | Clinical-Pathological Conference (CPC)

Thematic Analysis

1. Diagnostic Blind Spots in Severely Immunocompromised Hosts

Despite exhaustive antemortem evaluations—including serial multiplex PCRs, cultures, and high-resolution imaging—angioinvasive pulmonary aspergillosis eluded clinical detection. This highlights the limitations of non-invasive diagnostics in neutropenic patients with concomitant HLH and lymphoma, where pulmonary infiltrates are often reflexively attributed to drug toxicity, hemorrhage, or standard bacterial sepsis.

2. The Lethal Synergy of Immunosuppression and Lymphoma Transformation

The patient's clinical decline was driven by a multi-pronged immunological collapse:

• The Neoplastic Driver: Complete histological transformation from indolent NLPHL to aggressive THRLBCL, rendering standard chemo-immunotherapy (R-CHOP, R-GDP) ineffective.
  
  
• The Hyperinflammatory Driver: Secondary HLH characterized by extreme hyperferritinemia ($>91,000\text{ ng/mL}$) and tissue hemophagocytosis.
  
  
• The Infectious Driver: Profound cellular immune suppression permitting angioinvasive fungal proliferation.
  
  

3. The Irreplaceable Value of Post-Mortem Autopsy

This case underscores the gold-standard role of autopsy in modern medicine. Antemortem clinical diagnoses of "refractory septic shock and DIC" were clinically accurate descriptors of terminal physiology but etiologically incomplete. The autopsy successfully linked tissue-level structural failures—specifically pulmonary fungal angioinvasion and renal acute tubular necrosis with bile casts—to the patient's terminal pathway.

References

1. Cornillet, A., et al. (2006). "Documenting invasive aspergillosis in patients with hematological malignancy: a 4-year multicenter survey." Clinical Infectious Diseases, 43(5), 577-584. Available at: https://pubmed.ncbi.nlm.nih.gov/16886526/
   
   
2. Kousha, M., et al. (2011). "Pulmonary aspergillosis: a clinical review." European Respiratory Review, 20(121), 156-174. Available at: https://err.ersjournals.com/content/20/121/156
   
   
3. Chamilos, G., et al. (2006). "Autopsy findings in patients with hematologic malignancies and invasive mold infections." Haematologica, 91(2), 237-241. Available at: https://pubmed.ncbi.nlm.nih.gov/16431904/

Provide a Socratic steelman imrad summary, keywords and thematic analysis of the content below focusing on this question: 

Is pulmonary fungal infection detected on autopsy a cause of death or an indicator of imminent irreversible multi organ failure? Please provide searchable valid references with URLs in support of your statements.

[08/08, 19:04]hu2: Here's a quick analysis of the above CPC along with repeat of the printed data👇

CPC Clinical Handout (5th August 2026)*

*Patient particular: 32 Y/M), 

*Duration of hospital admission:* 26th February to 19th March 2026  

*Chief complaints:* Fever X 2 weeks

*Background history:*  

The patient was diagnosed with nodular lymphocyte predominant Hodgkin lymphoma (NLPHL-Pattern-A, Stage-IIA, cervical & axillary LN) and was on observation since 2018 (February) under CHMO with regular OPD follow-up. During the course there was transformation of NLPHL-Pattern-A to aggressive NLPHL-Patter-E (Stage-IVB) in 2025 (June), which was refractory to primary therapy of 6 cycles of R-CHOP (June - September 2025), followed by 3 cycles of R-GDP salvage therapy (November 2025- January 2026).

*History of presenting illness (HOPI):*

  

*H/o fever for 2 weeks:* Intermittent (102°F) a/w chills and generalized weakness. There was no history of evening rise of temperature and the fever was resolved partially with oral medications.  

There was no h/o cough, expectoration, pain abdomen, vomiting, loose-stools, burning micturition  

No h/o any bleeding manifestations, No h/o shortness of breath, chest pain, palpitation

*Past history:* No h/o DM, HTN, BA, TB, Hypothyroidism, CKD, *Family history:* nothing contributory  

*Personal history:* Mixed diet, no h/o any substance abuse

*General Physical Examination:*  

*Vitals:* PR- 94/min, BP- 120/70 mm Hg, RR- 18/min, SpO2- 98% @ RA, Temperature- 102°F  

Patient was conscious, co-operative, oriented to time & place  

*Pallor:* 1+, No palpable LAP, pedal oedema/icterus/cyanosis/clubbing: were absent

*Systemic examination:*  

*Respiratory:* B/L equal air entry, B/L normal vesicular breath sound, no crepitation/wheeze  

*Abdomen:* Soft, non-tender, palpable splenomegaly 10 cm below LCM, bowel sound-present  

*CVS and CNS:* WNL

*Investigation:*

*CBC*

Date 2018 2019 2022 2024 2025 26/2/26 2/3 8/3 13/3 18/3

**Hb (g/dl)** 16.3 16.9 16.6 16.9 8.0 5.4 6.7 7.4 5.9 4.4

**PLT (10⁹/L)** 283 124 140 158 59 32 26 8 3 2

**TLC (10⁹/L)** 13.9 7.4 5.30 6,12 1.77 1.6 1.73 0.9 0.36 0.4

**Neutrophil (%)** 72.0 58 38.0 50.8 27.1 58.3 40.2

**Lymphocytes (%)** 19.0 29 44.9 40.5 29.5 30.6 29.5

**Monocytes (%)** 8.0 11 16.3 8.1 43.4 11.1 27.0

**ANC (10⁹/L)** 10.0 1.02 0.60 0.88 0.24 0.21 0.16

*Biochemistry*

Date 2018 2025 2025 2026 2/3 8/3 13/3 15/3 16/3 18/3

**Na/K⁺ (mMol/L)** 138/4.0 131/4.0 132/4.0 131/3.4 131/4.2 128/3.9 129/4.9 130/4.9 131/4.5

**U/Cr (mg/dl)** 25.3/0.8 24/0.7 58/0.7 24/0.7 24/1.7 41/0.6 70/0.8 81/0.8 86/0.7 72/0.6

**AST/ALT (U/L)** 48/114 49/27 93/75 163/82 71/64 120/48 186/106 193/109 196/116 151/112

**ALP (U/L)** 92 61 142 149 163 403 320 262

**Bilirubin (T/D)(mg/dL)** 1.2/0.16 1.5/0.45 1.4/0.7 1.2/0.6 1.28 1.8/1.1 4.2/3.27 11.1/8.3 17.8/12.8 22.9/15.9

**Pro/Alb (g/dL)** 7.9/4.9 5.0/3.2 4.5/3.2 4.5/3.5 4.1/3.2 4.3/3.1 3.4/2.5 3.0/2.2 3.3/2.7 3.0/2.1

**Ca/Phos(mg/dL)** 8.7/3.2 8.3/3.3 7.9/3.1 7.9/3.6 8.8/2.8 9.9/4.1 10.5/3.4 10.4/2.1

**UA (mg/dL)** 6 6.1 6.5 4.3 6.8 5.2 3.4

**TG (mg/dL)** 386 185 350 364 267 278

**LDH (U/L)** 565 486 502 689 526 452 386

*Coagulation profile –*

Date:2026 26/02 02/03 09/03 12/03 16/03 18/03 19/03

**PT (Sec)** 13.3 12.7 12.6 13.2 15.3 17.4 27.2

**PTI (%)** 86 90 90 86 75 66 42

**aPTT (Sec)** 32.7 31.8 28.3 22.0 46.9 43.4 62.7

**INR** 1.16 1.11 1.10 1.16 1.34 1.52 2.37

**Fibrinogen (g/L)** 2.69 2.38 0.81 0.72 0.74 0.98

**D-dimer (ng/mL)** 2178 3608 917 640 626 399

*Blood Culture:* Sterile X4-BACTEC, *Urine culture:* Sterile X3  

*Urine RE/ME (09/03/2026):* Protein/Sugar-Nil, WBC-Nil, *24 hour urine protein:* 607.6 mg/TV (12/3)  

*Procalcitonin:* 2.78 ng/mL (09/03/26), 2.00 ng/mL (19/03)  

*Serum lactate:* 5.3 mmol/L (18/03)  

*Ferritin:* 16666 ng/mL (06/03), 91,695 ng/mL (16/03)  

*TFT (9/3):* TSH: 7.93 µIU/ml (0.27-4.2), T4: 6.11 µg/dL (4.8-12.7), T3: 0.64 ng/mL (0.8-2)  

*(26/11/25)T(SH):* 9.42 µIU/mL, T4: 6.67 µg/dL, T3: 0.77 ng/mL  

*HbA1c:* 5.5%, *25(OH)D3:* 11.2 (ng/mL), *PTH* (pg/mL): 6.5 (15-65)  

*S. Ammonia (µmol/L):* 115.9 (19-71)  

*Serum Immunoglobulin (mg/dL):* IgG: 295 (658-1837), IgM: 33 (40-263), IgA: 41 (71-360)  

*Viral markers:* HIV/HBV/HCV- nonreactive, EBV Viral load (PCR): not detected (10/03/26),  

*Multiplex PCR-Viral (InfeXon Labs):* Parvovirus B19: detected, HHV-6: detected

*USG abdomen (28/02/26):* Liver-16cm, spleen-23cm, (splenic vein- dilated, 13 mm); no free fluid  

*USG abdomen (17/03/26):* Liver 15.5 cm slightly raised echotexture; spleen 27.4 cm; Minimal pelvic ascites; *No IHBRD*  

*2D echocardiography (11/3):* Normal ejection fraction, no AS/AR/MS/MR/TS/TR, no clot/vegetation/, no PE/RWMA

*Cervical LN biopsy/slide review (S-3490/2018):* Hodgkin lymphoma, NLPHL-Pattern-A, positive for CD45, CD20, PAX5 and negative for CD3, CD30 and CD15. CD20 immunostain highlights the cellular nodules that are rich in CD20 positive B-cells. CD3 immunostain highlights fewer reactive T-cells in the background.

*Cervical LN biopsy (S-16040/2025):* As compared to the previous biopsy there was loss of nodular pattern, increase in neoplastic B-cells, decrease in mature B lymphocytes, and increase in T-cell with diminished PD-1 expressing T-follicular helper cells and PD-1 rosette. Features were suggestive of transformation of NLPHL Pattern-A to NLPHL Pattern-E.

*Bone marrow (A-1481/25, Tx-1181/25 on 28/05/2025):* Hypercellular marrow (cellularity 75-85%) with erythroid and megakaryocytic hyperplasia and proportionate granulocytic representation with no infiltration by lymphoma  

*Bone marrow (A-650/26, Tx-503/26 on 07/03/2026):* Hypercellular marrow (cellularity 75-85%) with erythroid preponderance. There was Prominence of histiocytes with significant erythrophagocytosis. There was Multifocal areas of infiltration by large atypical lymphoid cells with irregular nuclear contour, vesicular chromatin, multiple prominent nucleoli. Bone marrow was suggestive of infiltration by lymphoma along with hemophagocytosis.

*PET scan (30/01/2018):* Multiple discrete/confluent intensely FDG avid (SUVmax: 12.34) right axillary LN (largest 2.0X2.9 cm) with few subtle left axillary LN. Spleen was 14.2 cm; liver was 16.6 cm with normal physiological uptake. No significant enlarged or hyper-metabolic cervical LN was noted.

*PET scan (29/05/25/1181):* Few FDG avid (SUVmax: 20.07), level-II, III, IV cervical LN were noted. Multiple discrete/confluent intensely FDG avid (SUVmax:16.9) left supraclavicular, left paratracheal, paraesophageal and bilateral hilar mediastinal LN were noted. Liver was 18.7 with normal physiological uptake. Spleen was 22 cm with multiple FDG avid (SUVmax:16.3) hypodense infiltration. There were multiple abdominal and retroperitoneal FDG avid (SUVmax: 24.03) LN, largest 3.0X4.7 cm. There were multiple FDG avid (SUVmax: 12.9) marrow based lesions in right ischium, left pubic bone, sacrum, L5, L1 spinous process.

*PET scan (13/11/25):* Compared to the previous scan there was resolution of cervical LAP. Compared to the previous scan there was mild decrease in metabolic activity in mediastinal LAP (SUVmax: 14.7 Vs 16.9). Spleen was 22.08 cm with no significant interval changes (SUVmax: 16.9 Vs 16.3). Compared to the previous scan there was increase in numbers and mild increase in metabolic activity in abdominal and retroperitoneal LAP (SUVmax: 28.2 Vs 24.03). There were multiple FDG avid marrow based/ osseous lesions scattered throughout the axial and proximal appendicular skeleton and compared to the previous scan there was new lesions.

*PET scan (24/02/26):* There was resolution of cervical LAP. Compared to the previous scan, there was significant decrease in number, size and metabolic activity of the mediastinal LAP (SUVmax: 5.3 Vs 14.7). Spleen was 23.9 cm with increased in size and interval change (SUVmax: 10.5 Vs 16.9). Compared to the previous scan there was decrease in number, size and metabolic activity in abdominal and retroperitoneal LAP (SUVmax: 6.2 Vs 28.2). Compared to the previous scan there was new hypermetabolic osseous/marrow lesions.

*Course & management:* The patient was diagnosed with Hodgkin lymphoma (NLPHL-Pattern-A, Stage-IIA) and was under observation since 2018 with regular follow-up. During the course there was transformation of NLPHL-pattern-A to aggressive NLPHL-Pattern-E (Stage-IVB) in 2025, which was refractory to primary therapy of 6 cycles of R-CHOP, followed by 3 cycles of R-GDP. Now he presented with h/o intermittent fever (102°F) for 2 weeks without any localization symptoms. On evaluation his vitals were stable, had no palpable LAP but massive splenomegaly. Further evaluation revealed pancytopenia with febrile neutropenia [Hb-6.7 g/dL, TLC-0.9x10⁹/L, ANC-0.24x10⁹/L, Platelets-8x10⁹/L] and repeat bone marrow examination was suggestive of infiltration by lymphoma along with hemophagocytosis and the calculated H-score was suggestive of >99% probability for HLH with serum *Ferritin of 16666 ng/mL.* Intravenous Dexamethasone followed by Etoposide and IVIg were initiated for lymphoma associated secondary HLH. Polatuzumab was administered for underlying refractory lymphoma. Empiric broad-spectrum antibiotics along with antifungal therapy were continued and multiple units PRBC, RDP, SDAP, FFP were transfused throughout the course of illness. However patient condition deteriorated with persistent fever, new onset shock, and shortness of breath with CXR showing new interstitial infiltrates requiring oxygen therapy and inotropic support with worsening liver function and coagulopathy (INR-2.37), suggestive of hospital acquired infection with sepsis and DIC. Despite best possible measures condition worsened and developed altered sensorium with increasing drowsiness and irrelevant speech and subsequently had cardiac arrest and was declared dead on 19th March 2026.

*Unit’s final diagnosis:* Refractory nodular lymphocyte predominant Hodgkin lymphoma (NLPHL-pattern-A to pattern-E), secondary hemophagocytic lymphohistiocytosis (HLH), sepsis with multi organ dysfunction syndrome (MODS)  

*Cause of Death:* Type-I respiratory failure with refractory septic shock.

---

### *Summary of Key Clinical Points & Illness Trajectory*  

*Patient:* 32 Y/M

---

#### *1. Illness Trajectory with Time Stamps*

*2018 - Initial Diagnosis*  

- *Feb 2018*: Diagnosed with *Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) - Pattern A, Stage-IIA* involving cervical & axillary LN.  

- *30/01/2018 PET*: Right axillary LN FDG avid (SUVmax 12.34). Spleen 14.2 cm. Managed with observation + regular OPD follow-up.

*2025 - Transformation & Refractory Disease*  

- *June 2025*: Transformation to *aggressive NLPHL - Pattern E, Stage-IVB*.  

- *June - Sept 2025*: Received 6 cycles of R-CHOP → _Refractory_  

- *Nov 2025 - Jan 2026*: Received 3 cycles of R-GDP salvage therapy → _Refractory_  

- *29/05/2025 PET*: Widespread FDG avid disease - cervical, supraclavicular, mediastinal, abdominal, retroperitoneal LN + splenic + marrow lesions. Spleen 22 cm.  

- *13/11/2025 PET*: Some response in cervical/mediastinal nodes but new/progressive abdominal LN and new marrow/osseous lesions. Spleen 22.08 cm.

*Feb - March 2026 - Terminal Admission*  

- *26/02/2026*: Admitted to CHMO. Chief complaint: Intermittent fever 102°F x 2 weeks + generalized weakness.  

    - *Exam*: Stable vitals, no LAP, massive splenomegaly 10cm below LCM.  

    - *Labs*: Pancytopenia with febrile neutropenia - Hb 5.4, TLC 1.6, ANC 0.60, Plt 32. Splenomegaly on USG: 23cm.  

- *28/02/2026 USG*: Liver 16cm, Spleen 23cm, splenic vein dilated 13mm.  

- *07/03/2026 Bone Marrow*: Hypercellular with erythrophagocytosis + multifocal infiltration by large atypical lymphoid cells. Suggestive of *lymphoma infiltration + hemophagocytosis*.  

- *H-Score >99% for HLH*. *Ferritin 16666 ng/mL (06/03)* → rose to *91,695 ng/mL (16/03)*.  

- *Treatment initiated*: IV Dexamethasone + Etoposide + IVIg for secondary HLH. Polatuzumab for refractory lymphoma. Broad-spectrum antibiotics + antifungals. Multiple transfusions.  

- *Viral PCR*: Parvovirus B19 & HHV-6 detected.  

- *24/02/2026 PET*: Improvement in nodal disease but new hypermetabolic osseous/marrow lesions. Spleen increased to 23.9cm.  

- *18/03/2026*: Deterioration - Lactate 5.3, INR 1.52, Coagulopathy, Serum Ammonia 115.9.  

- *19/03/2026*: Worsened with shock, respiratory failure, altered sensorium, INR 2.37, DIC. *Cardiac arrest → Declared dead on 19th March 2026*.

---

#### *2. Key Clinical Points*

*Diagnosis*  

- *Primary*: Refractory NLPHL, transformed from Pattern-A to Pattern-E, Stage-IVB  

- *Complications*: Secondary Hemophagocytic Lymphohistiocytosis (HLH), Sepsis, DIC, MODS  

*Major Abnormal Findings*  

1. *Hematologic*: Progressive pancytopenia. Platelets dropped 283 → 2. Ferritin massively elevated. Hypogammaglobulinemia: IgG 295, IgM 33, IgA 41.  

2. *Organomegaly*: Progressive splenomegaly 14.2cm → 23.9cm. Hepatosplenomegaly.  

3. *Coagulopathy*: INR 1.16 → 2.37, Fibrinogen low 0.72-0.98, D-dimer high.  

4. *Liver*: Rising Bilirubin 1.2 → 22.9, AST/ALT 48/114 → 151/112, ALP 92 → 262.  

5. *Infections*: Parvovirus B19 + HHV-6 detected. Sterile blood/urine cultures.  

*Cause of Death*  

*Type-I respiratory failure with refractory septic shock* in the setting of refractory lymphoma, HLH, and multi-organ dysfunction.

---

This was a case of *transformation of indolent NLPHL to aggressive refractory disease complicated by HLH and sepsis*, leading to rapid deterioration despite intensive therapy.  

Pathology autopsy findings:

*WEDNESDAY STAFF CPC (05.08.2026)*  

32M  DOA: 26.02.2026  DOD: 19.03.2026  PM No. 33078*  

*Clinical Diagnosis:* Primary refractory Nodular lymphocyte predominant Hodgkin lymphoma post R-CHOP/R-GDP and Polatuzumab/etoposide with secondary HLH  

A complete autopsy was performed.

 External examination showed yellowish discoloration all over the body, abdominal distension, and pedal edema.

 The peritoneal cavity yielded straw-colored fluid (900ml) and the pericardial cavity (70ml); however, the pleural cavities were within normal limits.

*Antemortem Biopsies: S-3490/2018:* Sections showed partially effaced lymph node architecture by numerous, well-circumscribed lymphoid nodules. The nodules were predominantly composed of small mature lymphocytes admixed with scattered large atypical lymphocyte-predominant (LP) cells characterized by multilobulated or folded nuclei with delicate nuclear membranes, vesicular chromatin, and small but distinct basophilic nucleoli (“popcorn cells”). The LP cells were predominantly confined within the nodules. Background showed mature lymphocytes, while eosinophils, neutrophils, and plasma cells were inconspicuous. 

*LP cells: Positive for CD20+, PAX5 (strong)+, OCT2+, BCL6+. Negative for CD30-, CD15-* 

*Background:* Expanded CD21/CD23-positive follicular dendritic cell meshworks outlining nodules; PD-1/CD57-positive T-cell rosettes surrounding LP cells. The overall features were those of *Nodular Lymphocyte-Predominant Hodgkin Lymphoma, Pattern A (classic B-cell-rich nodular pattern).*

*S-16040/2025:* Sections showed fragmented lymph node tissue with marked architectural effacement by a diffuse lymphoid infiltrate without a discernible nodular growth pattern. The infiltrate is composed predominantly of numerous small mature lymphocytes and abundant histiocytes. Scattered throughout the diffuse background are large, atypical lymphocyte-predominant (LP) cells, occurring singly and occasionally in small, loose aggregates. These cells exhibited characteristic multilobulated ("popcorn") nuclei with irregular nuclear contours, vesicular chromatin, and one to several distinct basophilic nucleoli, with moderate pale cytoplasm. Well-formed follicular dendritic cell meshworks were absent, and residual reactive follicles were inconspicuous and not identified. LP cells were distributed diffusely throughout the lesion. T-cell rosettes around LP cells were typically absent or only focally identifiable. 

*LP cells: Positive for CD20+, PAX5 (strong)+, OCT2+, BCL6+. Negative: CD30-, CD15-.* 

*Background:* Predominantly CD3+/CD4+ T cells with numerous histiocytes; follicular dendritic cell meshworks (CD21/CD23) were absent. The overall features were those of *Nodular Lymphocyte Predominant Hodgkin Lymphoma, Pattern E (T-cell/Histiocyte-Rich Large B-cell Lymphoma-like pattern).*

*POSTMORTEM PERI-AORTIC AND MESENTERIC LYMPH NODES:*

 Occasional small lymph nodes measuring 1.5 to 2cm and cut surface; greyish white. Microscopy revealed a morphology similar to that of biopsy S-16040/2025. However, the atypical lymphoid cells were negative for CD20 (Post-R-CHOP/R-GDP therapy) but positive for PAX5. Also, the background did not show any reactive B-cells, and PD-1 expression was absent. The overall features were those of transformation to *T-cell/Histiocyte-Rich Large B-cell Lymphoma.*

*SPLEEN-* Enlarged and weighed 1900g. Cut surface congested; no focal lesion seen. Sections show diffuse effacement of the splenic architecture with obliteration of the white pulp by an infiltrate composed predominantly of small mature lymphocytes. Scattered singly throughout this background are large atypical lymphoid cells, comprising less than 10% of the total cellularity. These cells exhibit vesicular chromatin, irregular to multilobated nuclei, conspicuous eosinophilic nucleoli, and moderate amounts of pale cytoplasm. The red pulp was diffusely expanded and congested with Gamma-gandy bodies. In addition, evidence of hemophagocytosis was noted.

*LIVER-* Weighed 1800g. Enlarged. Capsular surface smooth, with greyish-white areas alternating with bile staining. Microscopy showed portal tract expansion by a similar lymphoid infiltrate composed predominantly of small mature lymphocytes, admixed with scattered large atypical lymphoid cells. The hepatocytes show mild reactive changes with steatosis, cholestasis, and foamy histiocyte collection. In addition, evidence of hemophagocytosis in the Kupffer cells was noted. 

*PANCREAS:* Grossly and microscopically unremarkable

*BONE MARROW:* Hypocellular for age. Marked reduction in normal hematopoietic elements; dominantly shows histiocytes with hemophagocytosis and infiltration by atypical lymphoid cells.

*HEART:* weighed 300g and is globular. Left ventricular wall thickness is 1.4cm, and the right ventricular wall is 0.4cm. All valves unremarkable, no thrombus seen. Microscopy revealed interstitial edema but no infiltration by lymphoma  

*LUNGS:* both together weighed 800g. Pleura was shiny, lungs were heavy and subcrepitant. Cut surface showed hemorrhagic nodules in the lower lobes of both lungs. Sections examined from these nodules revealed angioinvasive 

Pulmonary Aspergillosis.

*KIDNEYS-* Both kidneys together weighed 320g. The capsular surface is unremarkable, and the cut surface shows a distinct cortico-medullary distinction. Microscopy revealed tubular dilatation with shedding of the lining with a few bile casts. The glomeruli, interstitium, and vascular compartment were within normal limits.  

*GIT:* Unremarkable *SKELETAL MUSCLE, SKIN-* microscopically unremarkable *TESTIS:* Normal

FINAL AUTOPSY DIAGNOSIS (PM-33078)

A 32-year-old male with antemortem diagnosis of Nodular lymphocyte predominant Hodgkin lymphoma (Progressed from Pattern A to Pattern E) transformed to:

1. *T-cell/Histiocyte-rich Large B-cell Lymphoma* involving lymph nodes (abdominal), liver, spleen, and bone marrow

2. *Invasive Pulmonary Aspergillosis*

3. *Secondary Hemophagocytosis* ( liver, spleen, and bone marrow)

4. *Acute tubular necrosis*

### *Summary of Autopsy Findings*  

*Patient:* 32M | *DOD: 19.03.2026*  

*Background:* Known Primary refractory NLPHL, transformed Pattern A → Pattern E, treated with R-CHOP, R-GDP, Polatuzumab/etoposide. Treated for secondary HLH.

---

#### *Key Autopsy Findings by System*

1. *Lymphoreticular System*  

   - *Lymph Nodes, Spleen, Liver, Bone Marrow*: Diffuse infiltration by atypical large lymphoid cells with "popcorn" morphology. Transformation confirmed to *T-cell/Histiocyte-Rich Large B-cell Lymphoma (THRLBCL)* pattern - a more aggressive variant than antemortem Pattern E.  

   - *Spleen*: 1900g, massive. Diffuse effacement, hemophagocytosis present.  

   - *Bone Marrow*: Hypocellular with hemophagocytosis + infiltration by atypical lymphoid cells.

2. *Infectious Complications*  

   - *Lungs*: Hemorrhagic nodules in both lower lobes. Histology confirmed *angioinvasive Pulmonary Aspergillosis*.  

3. *Other Organ Findings*  

   - *Liver*: 1800g, enlarged. Portal infiltrate + steatosis, cholestasis, hemophagocytosis in Kupffer cells.  

   - *Kidneys*: Acute tubular necrosis with tubular dilatation, shedding, and bile casts.  

   - *Heart*: Interstitial edema, no lymphoma infiltration.  

   - *Peritoneal/Pericardial fluid*: 900ml + 70ml straw-colored fluid.  

   - *Other*: Pancreas, GIT, Skin, Skeletal muscle, Testis - unremarkable.

---

#### *New Insights Gained from Autopsy vs. Antemortem*

The antemortem diagnosis was already *refractory NLPHL Pattern E with secondary HLH*. The autopsy provided 4 key additional insights:

1.  *Confirmed Full Transformation to THRLBCL with Phenotypic Shift*  

    Antemortem biopsy S-16040/2025 called it "Pattern E - THRLBCL-like". Postmortem lymph nodes showed definitive transformation to *T-cell/Histiocyte-Rich Large B-cell Lymphoma* with loss of CD20 on atypical cells post-therapy, and absence of reactive B-cells + PD-1 rosettes. This confirms complete loss of the nodular microenvironment and a more aggressive B-cell phenotype than appreciated before. It explains the refractoriness to R-CHOP/R-GDP/Polatuzumab.

2.  *Documented Multi-organ Involvement by Lymphoma*  

    Antemortem imaging/PET showed nodal + marrow + splenic disease. Autopsy confirmed direct infiltration of *liver and bone marrow* by the transformed lymphoma, not just reactive changes. This established stage IV disease with hepatic involvement.

3.  *Identified Occult Fatal Infection: Invasive Pulmonary Aspergillosis*  

    This was _not_ in the antemortem clinical diagnosis. The hemorrhagic lung nodules and angioinvasive fungal hyphae were only found at autopsy. In the setting of neutropenia, high-dose steroids, etoposide, and HLH, this was likely a major contributor to respiratory failure and death. This highlights the risk of opportunistic fungal infection in heavily immunosuppressed lymphoma/HLH patients.

4.  *Confirmed Mechanism of Organ Failure*  

    Antemortem suggested "sepsis, DIC, MODS". Autopsy provided pathologic proof for:  

    - *Secondary Hemophagocytosis* in spleen, liver, bone marrow - explaining cytopenias and hyperferritinemia.  

    - *Acute Tubular Necrosis* in kidneys with bile casts - explaining renal dysfunction.  

    - *Hepatic involvement* by lymphoma + cholestasis + hemophagocytosis - explaining jaundice and LFT rise.  

---

#### *Final Autopsy Diagnosis*  

1.  *T-cell/Histiocyte-rich Large B-cell Lymphoma* involving lymph nodes, liver, spleen, and bone marrow  

2.  *Invasive Pulmonary Aspergillosis*  

3.  *Secondary Hemophagocytosis* 

4.  *Acute tubular necrosis*

*Bottom line:* The autopsy confirmed the aggressive transformation and multi-organ lymphoma spread, but most importantly it uncovered *invasive aspergillosis* as a previously unsuspected fatal complication, and provided tissue proof for HLH and ATN as causes of organ failure.

[08/08, 19:04]hu2: Can scroll down for the take home

[08/08, 19:10]hu1: Got it. 

Lung Aspergillosis is a tough one to beat in immunocompromised patients

UDLCO CRH: Bengal macro thrombocytopenia diagnostic uncertainty

 Summary

• Introduction:

  Clinicians frequently encounter diagnostic uncertainty when automated hematology analyzers report low platelet counts (pseudothrombocytopenia or true mild thrombocytopenia) alongside incidental observations of giant platelets on peripheral blood smears. Historically, patients traveling from the Bengal and eastern regions of the Indian subcontinent to southern hospitals (such as CMC Vellore) exhibited chronic, asymptomatic mild thrombocytopenia with giant platelets and familial aggregation, baffling routine diagnostic workflows and prompting extensive, unnecessary workups for conditions like Idiopathic Thrombocytopenic Purpura (ITP) or aplastic anemia.

• 
  

• 
  

• Methods:

  The trajectory of understanding evolved through clinical observations, retrospective case analyses, and collaborative peer-to-peer learning transcripts. Key milestones included the initial clinical recognition and formal reporting of the phenomenon as "Bengal Macrothrombocytopenia" (later named Harris Syndrome after the lead author) in 2002, followed by advanced molecular investigations—such as differential gene expression studies led by Kanjaksha Ghosh’s team under the ICMR. Modern medical communication networks and peer learning groups continue to utilize these historical insights to rapidly triage similar incidental peripheral smear findings across India.

• Results:

  What began as an isolated geographic anomaly transformed into a well-defined, benign congenital macrothrombocytopenia. Diagnostic pathways demonstrated that automated cell counters frequently undercount giant platelets (reporting low machine counts like 49,000–72,000/µL), whereas manual counts often reveal safer, borderline values (~1.4 lac/µL). Genetic clustering, lack of bleeding manifestations (normal bleeding/clotting times), and presence across family members successfully rule out dangerous acquired pathologies (e.g., ITP, TTP, or severe viral/infectious etiologies), sparing patients from aggressive interventions.

• 
  

• And (Discussion):

  The evolution from an incidental microscopic observation to Harris Syndrome highlights the value of regional epidemiological awareness in modern hematology. By recognizing the familial and geographical traits of Bengal Macrothrombocytopenia, clinicians across India can quickly resolve diagnostic dilemmas, differentiate benign congenital anomalies from life-threatening cytopenias, prevent patient anxiety, and avoid redundant, expensive diagnostic evaluations.

• 
  

Keywords

• Harris Syndrome

• Bengal Macrothrombocytopenia (BMTCP)

• Giant Platelets

• Peripheral Smear Uncertainty

• Automated vs. Manual Platelet Count

• Congenital Thrombocytopenia

• Regional Hematology (Eastern India / CMC Vellore)

Image CC licence: https://en.wikipedia.org/wiki/File:Giant_platelets.JPG

• 
  

Thematic Analysis

1. The Trajectory from Incidental Finding to Diagnostic Entity:

   The narrative details a classic medical evolution: an anomaly initially noticed as an isolated, confusing visual artifact on a peripheral smear (giant platelets coupled with low automated counts) among patients from eastern India. Through iterative clinical encounters and formal research (beginning at CMC Vellore in 2002 and later expanded via ICMR genomic studies), this localized curiosity was codified into a distinct clinical entity—Bengal Macrothrombocytopenia, or Harris Syndrome.

2. 
   

3. The Pitfalls of Automated Diagnostics vs. Manual Verification:

   A major theme revolves around technology-induced diagnostic anxiety. Automated hematology analyzers often misinterpret large platelets, leading to spuriously low machine counts. The transcripts emphasize how manual counting (~1.4 lac) serves as a vital corrective tool, exposing the technical limitations of automated counters when dealing with macrothrombocytes and preventing misdiagnoses of severe thrombocytopenia.

4. 
   

5. 
   

6. Benign Familial Traits vs. Pathological Acquired States:

   Clinicians navigating these cases frequently confront a differential diagnosis involving immune thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), or infection-induced drops. The thematic resolution relies on establishing a thorough clinical history: identifying a lack of bleeding symptoms, confirming normal coagulation profiles, and discovering similar "giant platelet" profiles across other family members transforms a frightening clinical puzzle into a benign, inherited trait.

7. 
   

8. Crowdsourced Peer Learning and the Democratization of Regional Medical Knowledge:

   The inclusion of conversational learning transcripts demonstrates how modern digital communication networks facilitate rapid clinical problem-solving. When physicians or learners encounter diagnostic uncertainty today, historical markers like "Bengal thrombocytopenia" are quickly shared across peer groups. This bridges historical academic discoveries (such as Ghosh's genetic expression studies) with frontline bedside decisions, enabling rapid resolution of peripheral smear uncertainties across India.

9. 
   

Provide an imrad summary, keywords and thematic analysis of the content below focusing on the relatively recent learning events trajectory that led to an incidental finding on peripheral smear noticed in humans from the Bengal and eastern region of the Indian subcontinent going on to becoming a diagnostic syndrome and how that learning is currently used to still resolve albeit quickly similar peripheral smear uncertainties across India.

More about giant platelets: https://en.wikipedia.org/wiki/Giant_platelet_disorder

More about Bengal thrombocytopenia aka Harris syndrome: https://en.wikipedia.org/wiki/Harris_platelet_syndrome

Image CC licence: https://en.wikipedia.org/wiki/File:Giant_platelets.JPG

Conversational learning Transcripts on Bengal macro thrombocytopenia 

[20/11/2025, 11:42]hu3: His platelets are low too. Either his spleen is big or his BM is hypoproliferative. With the retic count report I would think he is having extravascular hemolysis

[21/11/2025, 11:09]hu3: Excellent observation!

This is perhaps part of an interesting recent discovery from Bengali long distance patients to hospitals in the south aka Bengal Macro thrombocytopenia first reported in 2002 from CMC Vellore! https://www.amjmed.com/article/S0002-9343(02)01114-2/fulltext

Later it was renamed Harris syndrome after the first author from CMC Vellore: 

https://en.wikipedia.org/wiki/Harris_platelet_syndrome

The syndrome was subsequently developed further by Kanjaksha Ghosh's team (later retired as ICMR director) who studied the differential expression of genes in Bengal macrothrombocytopenia (BMTCP) here: https://www.sciencedirect.com/science/article/abs/pii/S1079979615001710?via%3Dihub

[21/11/2025, 13:06]hu3: But what is the explanation for reticulocytosis?

[21/11/2025, 13:09]hu2: Reactive marrow trying to fill in for hitherto unexplained anemia.

Reticulocytosis rules out aplastic anemia

[21/11/2025, 13:10]hu3: Yes. Spleen also rules out aplastic.

[21/11/2025, 13:11]hu3: Platelets may be low because of the Bengal thrombocytopenia described above

Conversational transcripts from another user driven learning group experiencing diagnostic uncertainty:

[24/06, 14:14]hu1: Platelet count 49000 to 70000 checked many times

1.4 lac manual count

Giant platelet 

Same complaint in family 

What can be reason?

[24/06, 14:15]hu4: Bleeding time?

[24/06, 14:15]hu1: Bt ct normal

[24/06, 14:15]hu1: PT inr normal

[24/06, 14:15]hu1: 5 times platelet is always low

[24/06, 14:16]hu1: No active complaint

[24/06, 14:16]hu4: vWB factor deficiency

[24/06, 14:16]hu6: Require exhaustive investigation for diagnosis

[24/06, 14:16]hu1: Giant platelet present in family members too

[24/06, 14:17]hu6: Full clinical history please

[24/06, 14:17]hu1: There is no complaint at all

[24/06, 14:17]hu1: In any family member

[24/06, 14:18]hu1: Scared of routine examination

[24/06, 14:18]hu1: 26 male no complaint

[24/06, 14:19]hu6: Is this some genetic syndrome

[24/06, 14:21]hu5: As per harrison

[24/06, 14:21]hu5: Can be congenital

[24/06, 14:22]hu5: Need to RULE out ITP first

[24/06, 14:22]hu6: Ok

[24/06, 14:25]hu4: ITP or TTP can be differential

[24/06, 14:25]hu6: Repeat testing for manual PC

[24/06, 14:25]hu1: This is repeated multiple times

[24/06, 14:26]hu5: Have HIV, HCV and H. pylori stool antigen

[24/06, 14:26]hu5: Have CRP levels slso

[24/06, 14:26]hu6: Manual is if above or near about 1.4 lac then it's ok

[24/06, 14:27]hu1: Esr crp normal

[24/06, 14:28]hu5: ....Perform this as well as it is directly linked with cause of thrombocytopenia

[24/06, 14:28]hu6: Check PC by manual in other family members also

[24/06, 14:28]hu5: Most common cause of infection induced thrombocytopenia other than Dengue or other acute viral syndromes

[24/06, 14:34]hu1: Yes they have 1.2 lac by manual and 72000 by machine

[24/06, 14:35]hu1: They also have giant platelet

[25/06, 21:21]hu2: This condition is called Bengal Macro thrombocytopenia first reported in 2002 from CMC Vellore! https://www.amjmed.com/article/S0002-9343(02)01114-2/fulltext

Subsequently developed further by Kanjaksha Ghosh's team (later retired as ICMR director) who studied the differential expression of genes in Bengal macrothrombocytopenia (BMTCP) here: https://www.sciencedirect.com/science/article/abs/pii/S1079979615001710?via%3Dihub

[25/06, 21:23]hu5: So basically it is type of Congenital Thrombocytopenianoccous

UDLCO CRH on Overdiagnosis and Care Pathways: Can we find the rabbit amidst the turtle and eagle through current standard cancer screening alone?

Analysis of Journal Club Discourse on Overdiagnosis and Care Pathways

 Introduction:

   Mass cancer screening guidelines implicitly rely on the premise that early detection of preclinical lesions directly translates into reduced mortality. However, recent large-scale meta-analyses demonstrate that while specific procedures (e.g., sigmoidoscopy) yield modest absolute gains in life expectancy (~110 days), overall life expectancy gains for most screening modalities (mammography, PSA, lung CT) remain uncertain or negligible when evaluated against all-cause mortality. This transcript analysis examines how clinicians and researchers evaluate the counterfactual problem of cancer behavior (the "turtle, rabbit, bird" taxonomy) and the structural factors sustaining high-volume screening.

 Methods:

   Qualitative textual analysis of a multi-participant online journal club transcript spanning two chronological nodes (January 2025 and August 2025/2026). Discussions were examined for thematic emergence, counterfactual logic regarding cancer epidemiology, and system-level critiques of clinical practice guidelines.

 Results:

   1. Epistemological Paradox: Participants highlighted that a individual's tumor trajectory (whether indolent "turtle," manageable "rabbit," or aggressively lethal "bird") cannot be definitively classified *prospectively* prior to the patient's terminal endpoint. Interventions obscure the natural history of the disease.

   2. Statistical vs. Clinical Relevance: Participants noted a disconnect between population-level relative risk reductions and individual absolute survival benefits, raising concerns about trade-offs with treatment-induced morbidities.

   3. Institutional Inertia ("Adverse Possession"): The discourse identified that high-volume screening pathways persist due to systemic, financial, and legal incentives that prioritize standard-of-care protocol adherence over individual counterfactual risk estimation.

 Discussion:

   Addressing the gap between population-level overdetection and individual-level benefit requires moving beyond static diagnostic labels to dynamic risk stratification (e.g., longitudinal surveillance, multiparametric MRI, and genomic profiling). However, adoption is hampered by the structural reliance of the healthcare system on existing screening infrastructure.

Keywords

 * Cancer Screening Adherence

 * Overdiagnosis & Over-detection

 * Counterfactual Dilemma

 * Biological Heterogeneity (Turtles, Rabbits, Birds)

 * All-Cause Mortality vs. Cancer-Specific Mortality

 * Institutional Inertia ("Adverse Possession" of Care Pathways)

 * Epistemological Reflexivity

Thematic Analysis: A Socratic Steelman Approach

Premise Under Debate:

"The 'rabbit' is mostly a statistical ghost conjured by over-detection, yet institutional inertia (the 'adverse possession' of standard-of-care pathways) keeps the screening machinery humming."*

> 

```

                     IS THE "RABBIT" A STATISTICAL GHOST?

                                      │

          ┌───────────────────────────┴───────────────────────────┐

          ▼                                                       ▼

  PRO-PREMISE (Contesting)                               ANTI-PREMISE (Defending)

(Screening creates ghosts)                              (Rabbits are real targets)

          │                                                       │

  ├── 1. The Epistemological Paradox                     ├── 1. Biological Reality

  ├── 2. Disconnect: Cancer-Specific vs. All-Cause       ├── 2. The Population Net-Benefit

  └── 3. Structural Incentives & Adverse Possession      └── 3. The Defensive & Ethical Mandate

```

#### **Theme 1: The Epistemological Status of the "Rabbit" (Over-detection vs. Real Risk)**

 * **Pro-Premise Steelman (Why the "rabbit" IS a statistical ghost):**

   * **The Counterfactual Blind Spot:** In clinical practice, once a lesion is detected and treated surgically or radiologically, its true natural history is permanently unobservable. A patient who survives 15 years post-prostatectomy without recurrence might have been a "turtle" (an indolent lesion that would never have caused harm) who was saved from non-existent danger.

   * **Population Over-detection:** High-sensitivity screening detects low-grade, slow-growing abnormalities. In aggregate, treating these indolent lesions creates the statistical illusion of "saved lives" (increasing survival rates) while doing little to alter the absolute number of deaths in the population.

 * **Anti-Premise Steelman (Why the "rabbit" IS NOT merely a ghost):**

   * **Biological Reality of Intermediate Tumors:** Cancer progression is not binary (solely harmless "turtles" or fatal "birds"). Intermediate-risk lesions ("rabbits") represent a distinct biological state that, if left unaddressed, can acquire metastatic potential over time.

   * **Risk-Stratified Interventions:** Modern clinical practice does not treat every detected lesion identically. The integration of multiparametric MRI, active surveillance, and genomic risk assays (e.g., Decipher, Oncotype DX) allows clinicians to observe tumor kinetics dynamically rather than assuming every screen-detected anomaly requires immediate ablation.

#### **Theme 2: Endpoint Metrics (Cancer-Specific Mortality vs. All-Cause Mortality & Quality of Life)**

 * **Pro-Premise Steelman (Critique of Screening Efficacy):**

   * **Lack of All-Cause Survival Benefit:** Meta-analyses show that most screening modalities demonstrate marginal or non-significant gains in overall life expectancy. A focus solely on disease-specific mortality ignores competing risks of mortality, particularly in older or multimorbid populations.

   * **Iatrogenic Harm:** Interventions triggered by overdetection carry real-world morbidity risks (e.g., urinary incontinence, erectile dysfunction, surgical complications, severe psychological anxiety) that can diminish the patient's quality of life without offering a proportional extension of lifespan.

 * **Anti-Premise Steelman (Defense of Screening Efficacy):**

   * **Methodological Demands of All-Cause Mortality:** All-cause mortality requires massive sample sizes and long follow-up periods to reach statistical power, making it a challenging primary endpoint for individual screening trials.

   * **Prevention of Advanced Stage Morbidity:** Reducing advanced-stage cancer incidence directly decreases the need for systemic chemotherapy, palliative interventions, and end-of-life suffering, providing clinical value beyond absolute longevity metrics alone.

#### **Theme 3: Systemic Mechanics ("Adverse Possession" vs. Standard of Care)**

 * **Pro-Premise Steelman (Institutional Inertia):**

   * **Path Dependency and Legal Safeguards:** Clinical guidelines, legal liability frameworks, and reimbursement models establish "standard of care" tracks that heavily incentivize screening and early intervention. Deviating from these established tracks carries medicolegal risk for individual practitioners.

   * **Economic Alignment:** The infrastructure surrounding screening—ranging from diagnostic imaging to downstream procedural management—represents a significant economic ecosystem. Re-evaluating screening thresholds or reducing screening volume presents structural and operational challenges for health systems built around high throughput.

 * **Anti-Premise Steelman (Justification of Standard Pathways):**

   * **Public Health Standardization:** Clear, population-wide screening guidelines ensure equitable access to early detection tools, mitigating disparities that arise when care pathways are overly discretionary or fragmented.

   * **Risk Mitigation and Duty of Care:** Standardized screening offers a systematic approach to identifying preventable, high-risk conditions early. From a public health perspective, the potential benefit of preventing late-stage diagnoses often outweighs the challenges associated with managing indolent cases.

Provide an imrad summary, key words and thematic analysis using a Socratic steelman approach contesting why and why not is "the "rabbit" mostly a statistical ghost conjured by over-detection, yet institutional inertia (the "adverse possession" of standard-of-care pathways) keeps the screening machinery humming."

Conversational transcripts from a journal club on "non adherence to cancer screening:

[16/01/2025, 09:29]hu1: ```Research Snippet 16th Jan’25```

*Social Risks and Cancer Screening Nonadherence*

How are social risks associated with nonadherence to the US Preventive Services Task Force cancer screening guidelines?

A recent JAMA Network Open study analyzed data from 147,000 US adults, revealing that social risks like life dissatisfaction, lack of social support, and food insecurity contribute to nonadherence to cancer screenings.

*3-2-1 Let’s Go!!*

*3 Key Points:*

- Social risks impact screening adherence, varying by sex and screening type.

- Modified Poisson regression analyzed data from the 2022 Behavioral Risk Factor Surveillance System.

- Targeted interventions addressing social determinants are crucial for improving screening rates.

*2 Takeaways:*

- Social determinants are globally relevant, including in India.

- Addressing social risks can improve health outcomes and increase preventive health measures participation.

*1 Question*: How can you modify this research topic to explore the impact of social risks on cancer screening adherence in India, considering specific social determinants like caste, economic status or urban-rural divides?

[16/01/2025, 10:01]hu2: Can we begin the brainstorm by challenging the audience here to find and analyse the evidence for the unreferenced first para in the introduction here and I quote:

"Routine cancer screenings are vital for early detection and prevention of more invasive cancers,

which improves treatment outcomes and reduces mortality rates significantly. For individuals at

average risk, routine cancer screenings facilitate the identification of preclinical cancer or

precancerous lesions. In some cases, they enable timely interventions, reducing the risk of advanced stage diagnoses, which are associated with poorer clinical outcomes."

Unquote 

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2828656

[16/01/2025, 10:06]hu2: 👆 particularly notice:

"In some cases, they enable timely interventions, reducing the risk of advanced stage diagnoses..."

What do they mean by some cases!? What number would "some" represent when their sample of screening-eligible adults are weighted to represent 78 784 149 US adults?

[16/01/2025, 10:12]hu1: Sir, I feel "some" is used generically because another meta-analysis (published in JAMA Open itself) states that screening for different cancers is not associated with statistically significant improvement(all-cause mortality) in survival of patients (except for sigmoidoscopy for CRC screening). But your point is important as they should have added references to it.

[16/01/2025, 10:19]hu2: Can you share the link to that other article?

[16/01/2025, 10:27]hu2: My other point in relation to screening was that there's often the tumor which could be a turtle or an eagle! 

Merely detecting the tumor without the ability to tell it's subsequent behaviour other than following up or god forbid killing the turtle for the low hanging fame while getting lacerated by the eagles talons once it begins to perch is any clinician's nightmare!

https://m.northcoastjournal.com/life-outdoors/cancer-part-2-turtles-birds-and-rabbits-12850085

[16/01/2025, 10:28]hu2: Here's a recent group discussion we had on this related note on the efficacy of screening👇

https://userdrivenhealthcare.blogspot.com/2024/12/udlco-on-digital-pathology-optimizing.html?m=1

[16/01/2025, 11:10]hu1: Sure sir

[16/01/2025, 11:12]hu1: https://youtu.be/ZCoKhHa6eZQ

Good evening everyone. 

The review of the week is here! 

Title- Estimated Lifetime Gained with Cancer Screening Tests- A meta-analysis of RCTs

Key takeaways:

1. The study had an interesting research question, how much do these screening tests increase the life in cancer patients? 

2. ⁠They included 18 trials with 10-15 years of follow up which had the following screening tests- 1. FOBT, Colonoscopy, sigmoidoscopy for CRC; Mammography for breast cancer; PSA for prostate cancer ; CT for lung cancer etc 

3. ⁠Among these statistically significant longevity increase was seen only in sigmoidoscopy with 110 days.

4. Increase in life expectancy in other cancers due to screening tests are uncertain. (Especially in prostate and lung cancer whereas mammography and fecal testing do not appear to extend life expectancy)

5. ⁠Several factors affecting longevity affect life expectancy in cancer patients like cardiovascular diseases, psychological burden etc. 

6. ⁠It’s therefore important for RCTs and studies to mention impact on all cause mortality via screening tests too in addition to cancer specific mortality. 

7. ⁠Limitations of study- Intention to treat analysis, longer follow ups , sample size and power.

[16/01/2025, 14:15]hu2: Statistical significance is misleading!

The clinical significance is apparent in the conclusion here 👇

"colorectal cancer screening with sigmoidoscopy may extend life by approximately 3 months; lifetime gain for other screening tests appears to be unlikely or uncertain."

Unquote

https://pmc.ncbi.nlm.nih.gov/articles/PMC10463170/

What's the clinical significance of getting to live three months longer? They haven't even mentioned quality of life but i suspect it wouldn't have been an easily liveable three months!

Thanks @⁨hu1⁩ for sharing this amazing study which is much better than the previous one and does challenge the rationale for current screening projects if not make them totally redundant!

Have we considered exploring the events timeline of patients with established malignancy to retrospectively try and fathom what could have predicted their first early occurrences in those particular individuals?

Same conversation revisited 7 months later:

[02/08, 07:34]hu2: Would be great if anyone could share some scientific studies that have looked at this hypothesis 👇

To quote,

"The real problem with the analogy, which is in widespread use, is that the rabbit is hypothetical. In real time, no patient actually knows if he is indeed a rabbit. Patients may believe they are/were rabbits; doctors may tell them they are/were rabbits. However, the truth is not revealed until the patient dies, and then only partially. This is unfortunate, clearly. A patient successfully treated surgically for his prostate cancer (i.e., is now alive and disease free) may indeed be a turtle. Once treated, it cannot be known with certainty what outcome the patient would have experienced had he not been treated. In addition, this same patient, apparently treated successfully with surgery, may tomorrow experience recurrence, and as such realize he is indeed a bird. This may happen at any point in the future, until the death of the patient.

More bluntly, a patient diagnosed with prostate cancer yet left untreated until death from another cause was indeed a turtle. A patient diagnosed with prostate cancer and treated aggressively yet still succumbed to his prostate cancer was a bird. Any patient diagnosed with prostate cancer and alive cannot with certainty be classified as a turtle, rabbit, or bird. Once he dies, we will know if he was or was not a bird. The best we can do is to assign probabilities to each of these with statistical models that look at the nature of the disease, treatment received, age of the patient, his comorbidities, etc."

Unquote https://pmc.ncbi.nlm.nih.gov/articles/PMC4865494/

[02/08, 08:31]hu1: I’ll try and search sir

[02/08, 08:41]hu3: There's a Physics professor who got Nobel Prize for exactly same stuff in around 1930s.

Ernst Schrodinger

[02/08, 08:42]hu3: Hypothetical rabbit is exactly his equations in medical form

[02/08, 08:48]hu3: Fun fact-Schrodinger actually hated the cat in the box experiment..He made those equations with Paul Dirac to roast how absurd quantum mechanics is if applied to real life and went on to get Nobel prize for those equations.

Only difference in your hypothetical rabbit experiment is that box is like some 20years followup data

@⁨hu2

[02/08, 08:50]hu2: Perhaps next 20 years of Orwellian digital trajectory mapping could show the answer

Dyadic conversations not in group:

[02/08, 08:40]hu1: 

Also, Gemini said this: 

For instance, Gulati et al. (2014) built a population microsimulation model (part of the NCI Cancer Intervention and Surveillance Modeling Network [CISNET]) to create a personalized nomogram. This tool calculates the exact probability that a newly screen-detected prostate cancer represents an overdiagnosed case (a "turtle") based on age, PSA, and Gleason score (Gulati et al., 2014).

[02/08, 08:43]hu2: Share the link if possible

[02/08, 08:46]hu1: https://share.gemini.google/bc0IoMzkUegW

[02/08, 08:47]hu2: I meant the link to the Gulati article with that quote shared by Gemini

[02/08, 08:48]hu1: Oh sure sir

[02/08, 08:48]hu1: https://doi.org/10.1093/jnci/djt367

Another group where the same conversation around the "hypothetical rabbit" spreads like a seismic wave:

[02/08, 07:54]hu4: Cool! These authors are definitely reflexively questioning 👏👏👏

The question is sufficient!

[02/08, 07:57]hu2: And since 10 years of this question what are the available answers is my current question

[02/08, 08:04]hu4: No answers... The question is "strategically ignored" as they say in corporate lingo

[02/08, 08:09]hu4: The answer lies in provenance... My opinion 

Whether the rabbit... Or the turtle... Neither can be proven... Coz the track (the race track) is not public

They could both be blamed for trespass (aka unscientific etc etc)

...

The strategy is to study the chain of ownership of the track... 

That has improved over the past 10 years (folks question consensus vs evidence)

...

But the system has its way too... Adverse possession, justified through utilization... In this context, maintaining status quo as the alternative paths are high cost

[02/08, 08:13]hu4: How AI read my response 

The core tension highlighted in that 2016 piece—the "turtle, rabbit, or bird" analogy for prostate cancer overdiagnosis and progression—remains one of oncology's most profound epistemological blind spots.

The article correctly identifies the ultimate paradox of modern screening:

 **the definitive pathological classification of a tumor's true biological nature is retrospective, visible only at the terminal endpoint of the host.**

Prospective certainty remains an illusion because intervening alters the timeline, and dying *with* a disease rather than *from* it is only clear post-mortem.

When looking at how the landscape has evolved over the last decade in response to this exact question, the "answers" haven't come from a magical biomarker that solves the counterfactual dilemma.

Instead, they’ve branched into a few uncomfortable structural shifts:

### 1. Moving from "Types" to "States" (Dynamic Surveillance)

Rather than trying to statically label a patient as a turtle or a rabbit on day one, modern urologic oncology has heavily leaned into active surveillance protocols backed by serial multiparametric MRI (mpMRI) and genomic risk classifiers (such as Decipher or Oncotype DX). The paradigm has shifted from *“Let's find out what kind of animal this is”* to *“Let's watch how fast the track is changing under our feet.”* 

Of course, as you noted, this still doesn't solve the core provenance problem—the unobserved counterfactual race remains hidden because you intervened the moment the trajectory looked suspicious.

### 2. The Overdiagnosis Quantinow

Population-level data over the last ten years has gotten much better at estimating the *denominator* of error. We now have robust long-term data from trials like ProtecT, showing that while radical treatments do little to change 10-to-15-year cancer-specific mortality for localized disease compared to active monitoring, they permanently lock the patient into lifelong morbidities (incontinence, erectile dysfunction). 

The medical establishment acknowledges the "rabbit" is mostly a statistical ghost conjured by over-detection, yet institutional inertia (the "adverse possession" of standard-of-care pathways) keeps the screening machinery humming.

### 3. The Economics of the Track

Your point about **provenance and the race track** hits the nail on the head. The reason the question is "strategically ignored" is that the multi-billion-dollar oncology ecosystem is built on managing the race, not questioning who laid down the asphalt. Admitting that millions of men are being treated for benign "rabbits" that were actually stationary rocks destabilizes the validity markers of the entire enterprise.

As for traditional medicine or alternative systemic frameworks entering this space—it’s an interesting frontier. When formal systems hit an epistemological wall where they can no longer differentiate between aggressive pathology and benign chronicity without destroying the patient's quality of life, looking at holistic homeostatic modulators or ancient empirical frameworks isn't just "alternative"—it’s an attempt to redesign the track entirely, focusing on host resilience rather than microscopic border warfare.

[02/08, 08:24]hu2: Will be grateful if you can share the prompt that led to this answer

[02/08, 08:26]hu4: Nothing special just our conversation

[02/08, 08:27]hu2: I'm trying to understand if there are parameters the LLM picks up which decides how it would like to satisfy the prompter? Very recently I learned from one of our PaJR patients, it could be something as simple as a hyphen!

Nowadays layer 1 of PaJR is restricted access so I'll probably have to archive that conversation separately as a drishtant

[02/08, 08:28]hu4: Please try it and let me know 

My regular AI holds a very extensive context of my work... So the response trajectories could be very different

[02/08, 08:29] hu 2 : Perhaps that's it. The LLM reacts differently to human conversational prompts (eavesdropping LLMs are a thing?) than to formal prompts?

[02/08, 08:29]hu4: Yes

Please explore RLHF and how it's done

It'll answer you (us) differently than it'll ..., ..., ...

[02/08, 08:31]hu2: So your prompt was like pasting the entire conversation right from the first text containing the article link?

[02/08, 08:31]hu4: Yes... That's it

[02/08, 08:32]hu2: So essentially the LLM is able to read the bias of the two conversationists and responds accordingly?

[02/08, 08:36]hu4: Not really biases... That you'll need to call for 

Context ontology - Yes! My context and contracts are public

(Though it's tedious right now and convergence takes a lot of affective register escalation... You'll need to be game enough to use that. Again... Use that with caution... The AI companies give leeway based on background. 

For instance they'll be more restrictive to me for medical topics. They will similarly push you back on affective register escalation)

[02/08, 08:37]hu2: Is context foundational to development of human bias?

[02/08, 08:38]hu4: Yes / no!

Depends on one's ability toward reflexivity?

Schoebers test demo

 [03/08, 14:59]hu2: OPD today

Young man with scleroderma, cutaneous vasculitic ulcers , digital infarcts, with spondyloarthropathy, severely reduced chest expansion of 1 cm with Schobers not done

[03/08, 21:41]hu2: Next patient had just low backache and while the schobers was forgotten in the previous patient where it was more likely to be positive, this image turned out to be a good demonstration of the elemental landmarks , bilateral si joint dimples and measurements that can be archived @hu1